Adams Share Discussion Threads

[letmepass] 10/6/2020 11:25

New lows.. LMFAO.. Its 70% owned by Richards. Now his mates are buying. Watch and learn

[dave4545] 10/6/2020 11:23

At least I'm not trying to pump a stock with a 16-43.55p spread

You've sunk to new lows lmp

[letmepass] 10/6/2020 11:03

He's clueless.. No idea. See his trades

[glavey] 10/6/2020 10:26

BTW Dave, it's the horse that seems worth backing, the reputation of the jockey is just an added assurance that it might perform when required. :-)

[thehitman1] 10/6/2020 10:15

first sell at 16p.

[oilbuy] 10/6/2020 10:04

You won't know the spread untill there is a sell !

[glavey] 10/6/2020 10:04

Sure, but you know that the real spread isn't as wide as the print.

[oilbuy] 10/6/2020 10:02

What happened to PHC Richard ?

[dave4545] 10/6/2020 10:00

Glavey

Even if the company is worth a punt who on earth is playing a stock with a 15-45p spread...I mean come on !

I know RG is involved and anything he touches causes spikes but it seems miles over NAV now and that spread..why even risk it

[glavey] 10/6/2020 09:57

dave, many times I'd agree with you but you may want to give it a bit more thought on this occasion.

[dave4545] 10/6/2020 09:55

So Mtph is 18.5p from 22p hardly a disaster

I have Lvcg from sub 12p :-))

[letmepass] 10/6/2020 09:44

Iam clueless what adck. Always late

[glavey] 10/6/2020 09:36

Someone (or two) was commenting on another thread recently that this was overlooked - can't recall just which thread it was just now. Seems the conversation was rather prescient!

[glavey] 10/6/2020 09:30

Seems to be some interesting potential going forward. There's time to pick up a few.

[vega44] 10/6/2020 08:10

Investment in Oxehealth Limited ("Oxehealth")
The Directors announce that, on 9 June 2020, Adams committed to subscribe for 21,630 new ordinary shares of £0.001 in Oxehealth at a price of £26.19 per share for a total cash consideration of £566,489.70 under a subscription agreement dated today ("Subscription Agreement"), which will raise gross subscription proceeds of £5 million for Oxehealth. Settlement of the cash consideration will be by way of payment of £339,893.82 on the first completion date of on or around 10 June 2020, followed by payment of £226,595.88 on the second final completion date of on or around 10 November 2020.
The Company's total holding of 21,630 ordinary shares of £0.001 in Oxehealth following the second final completion will represent 2.4% of the issued ordinary share capital of Oxehealth of 903,083 shares at that date. Adams is expected to have remaining cash balances of approximately £240,000 following this investment.
Richard Griffiths, who has an interest in 77.3% of Adams' issued share capital, has a current interest in 144,182 Oxehealth shares representing approximately 20.33% of Oxehealth's issued share capital, and Michael Bretherton, Chairman of Adams, holds 1,310 shares in Oxehealth representing 0.18% of its issued share capital. Richard Griffiths is subscribing for 15,274 new ordinary shares in Oxehealth under the Subscription Agreement for a consideration of £400,026 through his controlled undertaking, ORA Limited, and Mr Bretherton is subscribing for 1,528 new ordinary shares in Oxehealth under the Subscription Agreement for a consideration of £40,018. Following full completion of the Subscription Agreement, Mr Griffiths will have a total interest in 181,086 Oxehealth shares, including the Oxehealth shares held by Adams, representing 20.06% of Oxehealth's enlarged share capital. Other substantial shareholders in Oxehealth include the IP Group plc, which is also investing in the current funding round in order to maintain their interest of approximately 35% in Oxehealth's issued share capital held directly and through the IP Venture Fund II.
As a result of Michael Bretherton's personal interest in Oxehealth and his directorship of ORA Limited, he took no part in the Board's decision to invest in Oxehealth.
About Oxehealth
Oxehealth is involved in vision-based patient monitoring and management, using proprietary signal processing and computer vision to process normal digital video camera data to measure the vital signs and activity of patients. This is achieved through the deployment of their Digital Care Assistant (DCA) platform which consists of a fixed installation camera and illuminator, monitoring screens and software modules including the Vital Signs module, a Class IIa medical device cleared in Europe which represents a global first for a software. The platform enables clinicians to take non-contact cardiorespiratory measurements of patients' pulse and breathing rate, generates alerts to potentially risky activity and reports on patients' vital signs and behaviour, all without the clinician entering the patient's room.
The system offers measurable benefits in helping clinicians to improve the safety of both patients and carers. Since its commercialisation in 2018, the DCA been deployed into a number of different markets, primarily in Mental Health, Acute Hospital settings, Primary Care settings, Care Home, and Custodial facilities in both the UK and now in Sweden. Since launch, the DCA has achieved significant traction, being deployed in 30% of all NHS England Mental Health Trusts.
These partners have seen improvements in safety, quality and efficiency, with recent data* demonstrating:
· 48% reduction in falls in dementia facility
· 68% reduction in A&E visits from the dementia facility
· 49% reduction in emergency service visits
· 71% reduction in spend on enhanced observations

Recently, Oxehealth has reported that clinicians have made increasing use of the Oxehealth Service when caring for patients with COVID-19, both in Mental Health and also in Primary Care settings (General Practitioner COVID-19 Triage Hubs), due to its ability to limit clinician to patient contact whilst helping to maintain patient safety remotely.
With non-contact monitoring becoming increasingly important and clinically relevant, Oxehealth plans to further expand into Europe and North America.

The last filed accounts for Oxehealth are for the year ended 31 December 2018 and include a loss after tax of approximately £2.8 million, reflecting the continued significant investment in development and marketing in that year.

Barney Quinn, Chairman of Oxehealth, commented: "We would like to thank Adams Plc for contributing to the current successful funding round. The investment shows the faith in the Oxehealth Digital Care Assistant and the measurable benefits it brings to patients, clinicians and managing healthcare budgets. The investment funds will help Oxehealth on its continued expansion in the UK and internationally."

Further information on Oxehealth is available on the Oxehealth website www.oxehealth.com.

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

*Source data published in early 2020 by Coventry & Warwickshire Partnership NHS Trust with support from Oxehealth following an 8 month clinical study on the impact of using the Digital Care Assistant (DCA) on their dementia wards.

[vega44] 10/6/2020 07:35

Investment in Oxehealth Limited ("Oxehealth")
The Directors announce that, on 9 June 2020, Adams committed to subscribe for 21,630 new ordinary shares of £0.001 in Oxehealth at a price of £26.19 per share for a total cash consideration of £566,489.70 under a subscription agreement dated today ("Subscription Agreement"), which will raise gross subscription proceeds of £5 million for Oxehealth. Settlement of the cash consideration will be by way of payment of £339,893.82 on the first completion date of on or around 10 June 2020, followed by payment of £226,595.88 on the second final completion date of on or around 10 November 2020.
The Company's total holding of 21,630 ordinary shares of £0.001 in Oxehealth following the second final completion will represent 2.4% of the issued ordinary share capital of Oxehealth of 903,083 shares at that date. Adams is expected to have remaining cash balances of approximately £240,000 following this investment.
Richard Griffiths, who has an interest in 77.3% of Adams' issued share capital, has a current interest in 144,182 Oxehealth shares representing approximately 20.33% of Oxehealth's issued share capital, and Michael Bretherton, Chairman of Adams, holds 1,310 shares in Oxehealth representing 0.18% of its issued share capital. Richard Griffiths is subscribing for 15,274 new ordinary shares in Oxehealth under the Subscription Agreement for a consideration of £400,026 through his controlled undertaking, ORA Limited, and Mr Bretherton is subscribing for 1,528 new ordinary shares in Oxehealth under the Subscription Agreement for a consideration of £40,018. Following full completion of the Subscription Agreement, Mr Griffiths will have a total interest in 181,086 Oxehealth shares, including the Oxehealth shares held by Adams, representing 20.06% of Oxehealth's enlarged share capital. Other substantial shareholders in Oxehealth include the IP Group plc, which is also investing in the current funding round in order to maintain their interest of approximately 35% in Oxehealth's issued share capital held directly and through the IP Venture Fund II.
As a result of Michael Bretherton's personal interest in Oxehealth and his directorship of ORA Limited, he took no part in the Board's decision to invest in Oxehealth.
About Oxehealth
Oxehealth is involved in vision-based patient monitoring and management, using proprietary signal processing and computer vision to process normal digital video camera data to measure the vital signs and activity of patients. This is achieved through the deployment of their Digital Care Assistant (DCA) platform which consists of a fixed installation camera and illuminator, monitoring screens and software modules including the Vital Signs module, a Class IIa medical device cleared in Europe which represents a global first for a software. The platform enables clinicians to take non-contact cardiorespiratory measurements of patients' pulse and breathing rate, generates alerts to potentially risky activity and reports on patients' vital signs and behaviour, all without the clinician entering the patient's room.
The system offers measurable benefits in helping clinicians to improve the safety of both patients and carers. Since its commercialisation in 2018, the DCA been deployed into a number of different markets, primarily in Mental Health, Acute Hospital settings, Primary Care settings, Care Home, and Custodial facilities in both the UK and now in Sweden. Since launch, the DCA has achieved significant traction, being deployed in 30% of all NHS England Mental Health Trusts.
These partners have seen improvements in safety, quality and efficiency, with recent data* demonstrating:
· 48% reduction in falls in dementia facility
· 68% reduction in A&E visits from the dementia facility
· 49% reduction in emergency service visits
· 71% reduction in spend on enhanced observations

Recently, Oxehealth has reported that clinicians have made increasing use of the Oxehealth Service when caring for patients with COVID-19, both in Mental Health and also in Primary Care settings (General Practitioner COVID-19 Triage Hubs), due to its ability to limit clinician to patient contact whilst helping to maintain patient safety remotely.
With non-contact monitoring becoming increasingly important and clinically relevant, Oxehealth plans to further expand into Europe and North America.

The last filed accounts for Oxehealth are for the year ended 31 December 2018 and include a loss after tax of approximately £2.8 million, reflecting the continued significant investment in development and marketing in that year.

Barney Quinn, Chairman of Oxehealth, commented: "We would like to thank Adams Plc for contributing to the current successful funding round. The investment shows the faith in the Oxehealth Digital Care Assistant and the measurable benefits it brings to patients, clinicians and managing healthcare budgets. The investment funds will help Oxehealth on its continued expansion in the UK and internationally."

Further information on Oxehealth is available on the Oxehealth website www.oxehealth.com.

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

*Source data published in early 2020 by Coventry & Warwickshire Partnership NHS Trust with support from Oxehealth following an 8 month clinical study on the impact of using the Digital Care Assistant (DCA) on their dementia wards.

[vega44] 10/6/2020 07:35

A UK start-up is set to raise £5m ($6.3m) to meet demand for its software which turns video cameras into COVID-19 health monitors.
Oxehealth's programme can detect pulse and breathing rates from a distance, keeping care home and mental health trust staff safer.
The Oxford-based tech company is undergoing a funding round which is expected to close early next week, The Telegraph reports.
The round is being led by existing investors IP Group and Ora Capital, with the intention of pursing new regions, in particular Swedish care homes and US nursing facilities.
Oxehealth has already made deals to provide its software to 18 mental health trusts, two acute hospital trusts and two police forces across the UK and is piloting its technology in prisons.
The software works by using computer vision and signal processing to detect activity in a room, whilst using sensors to monitor pulse and breathing rates from a distance. This avoids the need to attach finger pulse oximeters, or wired clips to patient's fingers, allowing greater social distancing.
READ MORE: Coronavirus: Family pest control firm was handed £108m PPE contract
Oxehealth chief Hugh Lloyd-Jukes told The Telegraph: "We had interest from most mental health trusts in the UK before COVID-19, but it has provided an additional reason. What we've also seen now is the additional benefit of helping to reduce staff contact with patients because you can take pulse and breathing rates, understand the activity of patients without entering the room."
Lloyd-Jukes said new features had been rolled out during the pandemic including a "vital signs trends functionality," which monitors when there is a deterioration in pulse and breathing rate, which can be precursors to the deadly virus.
Recent figures from the Office for National Statistics suggest that almost a third of people in the UK have died from COVID-19 whilst in care homes.